Early Impact of Prescription Omega-3 Fatty Acids on Platelet Biomarkers in Patients with Coronary Artery Disease and Hypertriglyceridemia

Abstract

Independently of the dose and already at 1 week, short-term therapy with PO-3A provided a modest reduction of platelet activity biomarkers, despite concomitant aspirin and statin therapy, when compared to a placebo. The effect of PO-3A is unique, differs from other known antiplatelet agents and suggests potential pleiotropism. These preliminary randomized data call for confirmation in prospective studies.